Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseBreast CancerSubgroupHR+ postmenopausalICD10C50.-MeSHBreast NeoplasmsSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceDenosumabSupportive substanceDenosumabSupportive substanceDenosumabSupportive substanceDenosumabNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionsupportiveRisksBone PainDiarrheaDyspneaOsteonecrosis of the Jaw only studiesPublicationAuthorGnant MDiseasenicht metastasiertes, HR+ Mamma-Ca, postmenopausal, adjuvant kombiniert mit Aromatase-Inhibitor TherapieOriginDepartment of Surgery and Comprehensive Cancer Center, Medical University of Vienna, ABCSG-18Protocols in Revision 1 protocol foundProtocols under revision.Denosumab 60, Breast Cancer, adjuvant (PID884 V1.0)
